We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
News

RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market

RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
News

RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rainbow Coral Corp. opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector.

Transdermal patches are an increasingly popular drug delivery system that is being developed for everything from contraception to Parkinson's disease. Transdermal drug delivery prevents many of the problems associated with oral and intravenous routes and offer major advantages such as improved bioavailability, more uniform plasma levels, longer duration of action, reduced side effects and improved therapy.

Some analysts have predicted that the transdermal delivery market could be worth as much as $31.5 billion by 2015 from a value of $21.5 billion just three years ago. RBCC expects that partnering with an emerging leader in the sector could help the company capture a big piece of that growth.

“Transdermal patches offer a non-invasive option for treating many diseases and disorders,” said RBCC CEO Patrick Brown. “The appeal is obvious. We’re in negotiations now with a patch developer we believe has high profit potential, and we’re optimistic that a deal can be struck soon.”

Advertisement